All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-03-07.
From the record
Profound Medical Corp.'s filings since 2017 show 1 warning event: a warning not to rely on past financial statements (8-K item 4.02, the latest 2025-03-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+49.5% a year over 3 filed years; profitable in 0 of 3.
From the record
Profound Medical Corp.'s 3 filed years say what it did: revenue went from $7 million in fiscal 2023 to $16 million in fiscal 2025, up 49.5% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Profound Medical Corp.'s shareholder treatment is put at 3.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 38% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -64%: lost 64¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Profound Medical Corp. lost about 64 cents for every dollar of shareholders' money, and gross profitability: its products earned about 15 cents per dollar of everything the company owns. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 22.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 43% of 109 in its family; net margin -264.4%.
From the record
Profound Medical Corp.'s standing among 109 graded names in its industry family: revenue of $16 million in fiscal 2025 ranks in the bottom 25% by size; a net margin of -264.4% ranks in the bottom 19%; revenue growth of 49.5% a year over the last 2 filed years ranks in the top 16% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Profound Medical Corp.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 105 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 34% of 104 in its family for room to expand.
From the record
Profound Medical Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $60 million against debt of $4 million leaves 71.3% of its assets as net cash, top 7% of its family; cash from operations less capital spending is -238.4% of revenue (bottom 16%); a gross margin of 70.8% (top 30%); research spending of 127.9% of revenue (top 13%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 27% of 105 in its family for growth drivers.
From the record
Profound Medical Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 49.5% a year over the last three filed years against 49.5% over all 3, speeding up (top 43% of its family); the newest year grew 50.8% (top 13%); research spending grew 19.5% a year (top 24%) (its annual reports). Profound Medical Corp. reported 2 product lines in fiscal 2025: Recurring Non Capital at $10 million (60%), Capital Equipment at $6 million (40%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.1/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Profound Medical Corp.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 88 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made